ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non‐small cell lung cancer
-
Published:2022-01-01
Issue:2
Volume:40
Page:265-273
-
ISSN:0167-6997
-
Container-title:Investigational New Drugs
-
language:en
-
Short-container-title:Invest New Drugs
Author:
Ku Bo Mi, Heo Jae Yeong, Kim Jinchul, sun Jong-Mu, Lee Se-Hoon, Ahn Jin Seok, Park Keunchil, Ahn Myung-JuORCID
Abstract
SummaryThe emergence of acquired resistance limits the long-term efficacy of EGFR tyrosine kinase inhibitors (EGFR TKIs). Thus, development of effective strategies to overcome resistance to EGFR TKI is urgently needed. Multiple mechanisms to reactivate ERK signaling have been successfully demonstrated in acquired resistance models. We found that in EGFR mutant non-small cell lung cancer (NSCLC) patients, acquired resistance to EGFR TKIs was accompanied by increased activation of ERK. Increased ERK activation was also found in in vitro models of acquired EGFR TKI resistance. ASN007 is a potent selective ERK1/2 inhibitor with promising antitumor activity in cancers with BRAF and RAS mutations. ASN007 treatment impeded tumor cell growth and the cell cycle in EGFR TKI-resistant cells. In addition, combination treatment with ASN007 and EGFR TKIs significantly decreased the survival of resistant cells, enhanced induction of apoptosis, and effectively inhibited the growth of erlotinib-resistant xenografts, providing the preclinical rationale for testing combinations of ASN007 and EGFR TKIs in EGFR-mutated NSCLC patients. This study emphasizes the importance of targeting ERK signaling in maintaining the long-term benefits of EGFR TKIs by overcoming acquired resistance.
Funder
the Collaborative Genome Program for Fostering New Post-Genome Industry of the National Research Foundation (NRF) funded by the Ministry of Science and ICT
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference25 articles.
1. Kuwano M, Sonoda K, Murakami Y, Watari K, Ono M (2016) Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer. Pharmacol Ther 161:97–110. https://doi.org/10.1016/j.pharmthera.2016.03.002 2. Ku BM, Choi MK, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ (2018) Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model. PLoS One 13(4):e0194730. https://doi.org/10.1371/journal.pone.0194730 3. Becker JH, Gao Y, Soucheray M, Pulido I, Kikuchi E, Rodriguez ML, Gandhi R, Lafuente-Sanchis A, Aupi M, Alcacer Fernandez-Coronado J, Martin-Martorell P, Cremades A, Galbis-Caravajal JM, Alcacer J, Christensen CL, Simms P, Hess A, Asahina H, Kahle MP, Al-Shahrour F, Borgia JA, Lahoz A, Insa A, Juan O, Janne PA, Wong KK, Carretero J, Shimamura T (2019) CXCR7 reactivates ERK signaling to promote resistance to EGFR kinase inhibitors in NSCLC. Cancer Res 79(17):4439–4452. https://doi.org/10.1158/0008-5472.CAN-19-0024 4. Tricker EM, Xu C, Uddin S, Capelletti M, Ercan D, Ogino A, Pratilas CA, Rosen N, Gray NS, Wong KK, Janne PA (2015) Combined EGFR/MEK inhibition prevents the emergence of resistance in EGFR-mutant lung cancer. Cancer Discov 5(9):960–971. https://doi.org/10.1158/2159-8290.CD-15-0063 5. Ercan D, Xu C, Yanagita M, Monast CS, Pratilas CA, Montero J, Butaney M, Shimamura T, Sholl L, Ivanova EV, Tadi M, Rogers A, Repellin C, Capelletti M, Maertens O, Goetz EM, Letai A, Garraway LA, Lazzara MJ, Rosen N, Gray NS, Wong KK, Janne PA (2012) Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov 2(10):934–947. https://doi.org/10.1158/2159-8290.CD-12-0103
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|